×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 9B2: Clinical Pharmacology: What In The World Are They Talking About and What’s In It For Me?
Session Chair(s)
Stephanie L. Byrdé, BSN, MS, RN
Advisor, Scientific Communications, Clinical Pharmacology
Eli Lilly & Company, United States
Clinical Pharmacology is frequently misunderstood; it’s an enigma to many people. The truth is you need to understand where Clinical Pharmacology plays and when you need to involve your Clinical Pharmacology writer. Clinical Pharmacology writers are important from a molecule’s first human dose all the way through launch, so understanding the unique abilities and strengths of this group is beneficial to you and your team.
Learning Objective : At the conclusion of this session, participants should be able to:- Discern the difference between Clinical Pharmacology trials and biopharmacology trials
- Describe how clinical pharmacology influences the clinical plan and label for every molecule under development
- Verbalize clinical pharmacology’s role in dose decisions
Speaker(s)
Clinical Pharmacology Medical Writers ‘Drug Development Accelerators’
Lisa Toth
Eli Lilly and Company, United States
Scientific Communications Consultant
Clinical Pharmacology: What in the World are They Talking About and What’s in it for Me?
Stephanie Brillhart, MS
Inventiv Health, United States
Manager, Medical Writing
Panel Discussion
All Session Speakers, United States
Have an account?